KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Retained Earnings (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Retained Earnings for 13 consecutive years, with $335000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 100.04% to $335000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $335000.0, a 100.04% increase, with the full-year FY2025 number at $335000.0, up 100.04% from a year prior.
  • Retained Earnings was $335000.0 for Q4 2025 at Xenon Pharmaceuticals, up from -$1.1 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $335000.0 in Q4 2025 to a low of -$1.1 billion in Q3 2025.
  • A 5-year average of -$325.6 million and a median of -$3.1 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 1168042.86% in 2024, then surged 100.04% in 2025.
  • Xenon Pharmaceuticals' Retained Earnings stood at -$990000.0 in 2021, then tumbled by 203.03% to -$3.0 million in 2022, then skyrocketed by 97.43% to -$77000.0 in 2023, then crashed by 1168042.86% to -$899.5 million in 2024, then soared by 100.04% to $335000.0 in 2025.
  • Per Business Quant, the three most recent readings for XENE's Retained Earnings are $335000.0 (Q4 2025), -$1.1 billion (Q3 2025), and -$1.0 billion (Q2 2025).